Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-09-04
2007-09-04
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388220, C530S388800, C530S388850, C435S328000, C435S344100, C435S372000, C435S372300, C424S134100, C424S135100, C424S143100, C424S155100
Reexamination Certificate
active
11477572
ABSTRACT:
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc: ζ receptor where Fv designates the VHand VLchains of a single chain monoclonal antibody to CE7 linked by peptide, Fcrepresents a hinge-CH2-CH3 region of a human IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.
REFERENCES:
patent: 5912172 (1999-06-01), Eshhar et al.
patent: 6410319 (2002-06-01), Raubitschek et al.
patent: WO9715669 (1997-05-01), None
patent: WO 00/23573 (2000-04-01), None
patent: WO 00/31239 (2000-06-01), None
Nolan et al. Clinical Cancer Research, 5(12):3928-3941, 1999.
Gonzalez et al. Journal of Genetic Medicine, 6(6):704-711, 2004.
Hombach et al. Int. J. Mol. Med., 2(1):99-103, 1998.
Sadelain et al. Nature Reviews, 3:35-45, 2003.
Jensen, M et al. “CD20 Is A Molecular Target For scFvFc:ζ Receptor Redirected T Cells: Implications For Cellular Immunotherapy of CD2+Malignancy,”Biology of Blood and Marrow Transplantation,4:75-83, 1998.
Abken, H. et al. “Chimeric T-Cell Receptors: Highly Specific Tools To Target Cytotoxic T-Lymphocytes To Tumour Cells,”Cancer Treatment Reviews,23:97-112, 1997.
Nicholson, Ian C. et al. “Construction And Characterisation Of A Functional CD19 Specific Single Chain Fv Fragment . . . ,”Molecular Immunology,vol. 34, No. 16-17, 1157-1165, 1997.
Jensen, M. C. et al. Abstract #98: “Targeting Pre-B Acute Lymphoblastic Leukemia With T Cell Clones Engineered To Express A CD19-Specific Chimeric Immunoreceptor,” Blood, 96(11), p. 26A, Nov. 16, 2000.
Amstutz, H. et al. “Production And Characterization Of A Mouse/Human Chimeric Antibody Directed Against Human Neuroblastoma,”,Int. J. Cancer,53:147-152, 1993.
D'Uscio et al., Journal of Immunological Methods, 146:63-70, 1992.
Heuser et al., Gene Therapy, 10:1408-1419, 2003.
Cross et al., Molecular Biology of the Cell, 13:2881-2893, 2002.
Blanchard David J.
City of Hope
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
CE7-specific chimeric T cell receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CE7-specific chimeric T cell receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CE7-specific chimeric T cell receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3801724